NOVO.B.DK

244.2

-5.42%↓

HLUNB.DK

39.22

+0.05%↑

AMBUB.DK

79

+0.38%↑

NOVO.B.DK

244.2

-5.42%↓

HLUNB.DK

39.22

+0.05%↑

AMBUB.DK

79

+0.38%↑

NOVO.B.DK

244.2

-5.42%↓

HLUNB.DK

39.22

+0.05%↑

AMBUB.DK

79

+0.38%↑

NOVO.B.DK

244.2

-5.42%↓

HLUNB.DK

39.22

+0.05%↑

AMBUB.DK

79

+0.38%↑

NOVO.B.DK

244.2

-5.42%↓

HLUNB.DK

39.22

+0.05%↑

AMBUB.DK

79

+0.38%↑

Search

Coloplast A-S (Class B)

Deschisă

492 2.39

Rezumat

Modificarea prețului

24h

Curent

Minim

478.3

Maxim

492.8

Indicatori cheie

By Trading Economics

Venit

522M

1.4B

Vânzări

83M

7B

P/E

Medie Sector

27.421

110.024

EPS

6.32

Randament dividend

4.84

Marjă de profit

19.835

Angajați

16,983

EBITDA

309M

2.3B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.84%

2.26%

Următoarele câștiguri

12 mai 2026

Data viitoare de dividende

20 mai 2026

Următoarea dată ex-dividende

18 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-9.1B

110B

Deschiderea anterioară

489.61

Închiderea anterioară

492

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb. 2026, 22:36 UTC

Câștiguri

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb. 2026, 22:32 UTC

Câștiguri

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

23 feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb. 2026, 23:39 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb. 2026, 23:27 UTC

Câștiguri

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb. 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb. 2026, 22:31 UTC

Câștiguri

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb. 2026, 22:24 UTC

Câștiguri

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb. 2026, 22:20 UTC

Câștiguri

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat